8-K: Zynex Repurchases 1.7 Million Shares from CEO in Exempt Transaction

Zynex, Inc. repurchased 1.7 million shares of its common stock from Chairman, President, and CEO Thomas Sandgaard at a price of $2.905 per share.

Summary

• On March 13, 2025, Zynex, Inc. purchased 1,700,000 shares of its common stock from Thomas Sandgaard, the Chairman, President, and CEO.
• The transaction was exempt under Rule 16b-3.
• The purchase price was $2.905 per share, which was the closing price of the common stock on the date of the transaction.
• The Audit Committee and disinterested members of the Board of Directors approved the transaction.
• The board considered the potential impact on earnings per share, book value per share, and the effect of open market sales by Mr. Sandgaard.
• The board determined the transaction was on terms no less favorable to the Company than terms that could have been reached with an unrelated third party, reasonable, and at arms length.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The share repurchase is generally a positive sign, indicating management believes the company is undervalued. The transaction was approved by disinterested parties, suggesting good governance.

Positives

• The share repurchase could potentially increase earnings per share and book value per share for remaining shareholders.
• The transaction was deemed fair and at arm's length by the disinterested board members and the Audit Committee.
• The company avoided potential market disruption from the CEO selling shares on the open market.

Industry Context

Share repurchases are a common way for companies to return value to shareholders, especially when they believe their stock is undervalued. Insider transactions are closely scrutinized and require careful consideration of fairness and potential conflicts of interest.

Comparison to Industry Standards

• Share repurchases are a common capital allocation strategy, often compared to dividend payouts or acquisitions.
• The fairness of the price is benchmarked against the prevailing market price, as was done in this case by using the closing price on the transaction date.
• Similar transactions involving insider sales are often compared to those of companies like Medtronic or Boston Scientific, which also operate in the medical device space, to ensure compliance and fairness.

Related Party Transactions

• The purchase of shares from the CEO, Thomas Sandgaard, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may benefit from the potential increase in earnings per share and book value per share.
• The company's cash reserves are reduced by the amount spent on the share repurchase.

Key Dates